Helen Tayton-Martin

Company: Adaptimmune

Job title: Chief Business & Strategy Officer

Seminars:

T-Cell Therapies in the Real World 9:00 am

• Phase 1b clinical data on IMA203 demonstrate deep and durable responses in heavily pretreated metastatic melanoma patients at RP2D • Next-generation IMA203CD8 Phase 1a dose escalation data show enhanced pharmacology and potency per cell; to be evaluated for future in development in solid cancers with medium-level PRAME copy numbers • SUPRAME, randomized-controlled Phase 3…Read more

day: Day 1